BIOCRYST PHARMACEUTICALS INC 8-K

What Happened
BioCryst Pharmaceuticals, Inc. announced on January 9, 2026 (Regulation FD disclosure) that it is increasing the U.S. wholesale acquisition cost (WAC) for ORLADEYO® (berotralstat). The WAC will rise from $44,484.33 to $48,487.92 per 28‑day pack (for either 150 mg or 110 mg capsules), effective January 9, 2026. The company noted this disclosure is made under Regulation FD and said the information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act, nor incorporated by reference into other filings except as expressly stated.

Key Details

• Effective date: January 9, 2026.
• Product: ORLADEYO® (berotralstat), 28-day pack of 150 mg or 110 mg capsules.
• WAC change: from $44,484.33 → $48,487.92 per 28‑day pack.
• Disclosure type: Regulation FD; not deemed "filed" under Section 18 of the Exchange Act.

Why It Matters
A change in WAC updates the drug's official list price used in market reporting, payer negotiations, and some pricing calculations. For investors, this is a company-announced pricing action that updates the published list price for ORLADEYO in the U.S.; any effects on revenue, reimbursement, or access will depend on payers, contracts, and subsequent company disclosures.